Ischemia-modified Albumin and Heart Fatty Acid–binding Protein: Could Early Ischemic Cardiac Biomarkers Be Used in Acute Stroke Management?
Received 6 April 2009; received in revised form 16 June 2009; accepted 1 July 2009. published online 17 May 2010.
Background
The detection of biomarkers such as ischemia-modified albumin (IMA) and heart fatty acid–binding protein (HFABP) is used in the early diagnosis of acute myocardial infarction. As these biomarkers are not organ specific, we tested them in the neurovascular field.
Methods
A total of 41 patients with acute stroke were enrolled (31 ischemic strokes and 10 intracerebral hemorrhages). IMA and HFABP levels were measured in serum samples collected within 4.5hours of stroke onset. Clinical, imaging, and outcome data were recorded.
Results
No difference in baseline IMA or HFABP was found between patients with ischemic and hemorrhagic stroke. There was no correlation among biomarker levels at admission, National Institutes of Health Stroke Scale score, or stroke volume. Neither of the biomarkers could predict short-term prognosis.
Conclusions
IMA and HFABP do not appear to be relevant in acute stroke management.
∗Department of Neurology and Stroke Unit, University Hospital, Nantes, France
†Department of Biochemistry, University Hospital, Nantes, France
‡Department of Neuroradiology, University Hospital, Nantes, France
Address correspondence to Fanny Herisson, MD, Department of Neurology and Stroke Unit, Laennec Hospital, Boulevard Monod, FR-44093 Nantes Cedex, France.
ABSTRACT